---
title: "CG Oncology (NASDAQ:CGON) Trading Down 0.9%"
description: "CG Oncology (NASDAQ:CGON) stock price was down 0.9% on Thursday, trading as low as $29.26. Analysts have set new price targets and institutional investors have made changes to their positions in the s"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/207481404.md"
published_at: "2024-06-28T06:23:07.000Z"
---

# CG Oncology (NASDAQ:CGON) Trading Down 0.9%

> CG Oncology (NASDAQ:CGON) stock price was down 0.9% on Thursday, trading as low as $29.26. Analysts have set new price targets and institutional investors have made changes to their positions in the stock. CG Oncology focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer.

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report)'s stock price was down 0.9% on Thursday . The stock traded as low as $29.26 and last traded at $30.25. Approximately 408,077 shares were traded during trading, a decline of 39% from the average daily volume of 672,452 shares. The stock had previously closed at $30.52.

## Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CGON shares. The Goldman Sachs Group raised shares of CG Oncology from a "neutral" rating to a "buy" rating and lifted their price target for the company from $43.00 to $50.00 in a research note on Monday, May 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $75.00 target price on shares of CG Oncology in a research note on Thursday, May 2nd. Finally, HC Wainwright reiterated a "buy" rating and set a $75.00 price target on shares of CG Oncology in a report on Tuesday, May 28th.

**Read Our Latest Report on CG Oncology**

## CG Oncology Trading Down 0.9 %

The stock's fifty day moving average price is $33.57.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The company had revenue of $0.53 million for the quarter. As a group, analysts forecast that CG Oncology, Inc. will post -1.71 EPS for the current year.

## Hedge Funds Weigh In On CG Oncology

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of CG Oncology during the first quarter worth about $102,000. California State Teachers Retirement System acquired a new position in CG Oncology in the first quarter valued at approximately $103,000. BNP Paribas Financial Markets acquired a new position in CG Oncology in the first quarter valued at approximately $492,000. Capstone Investment Advisors LLC acquired a new position in CG Oncology in the first quarter valued at approximately $806,000. Finally, Blackstone Inc. acquired a new position in CG Oncology in the first quarter valued at approximately $1,098,000. 26.56% of the stock is owned by institutional investors and hedge funds.

## CG Oncology Company Profile

(Get Free Report)

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

## Featured Stories

-   Five stocks we like better than CG Oncology
-   Russell 2000 Index, How Investors Use it For Profitable Trading
-   BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
-   How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
-   Progress Software Stock Back in the Green After Beating Forecasts
-   How to Use the MarketBeat Excel Dividend Calculator
-   Goldman Sachs Raises Stock Target for Affirm: Key Insights

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ Elon’s Next IPO Could be Bigger than Tesla (From Paradigm Press) (Ad)## Should you invest $1,000 in CG Oncology right now?

Before you consider CG Oncology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.

While CG Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [CGON.US - CG oncology](https://longbridge.com/en/quote/CGON.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| OXY-Clean: Buffett's Favourite Oil Rig Scrubs $6 Billion In Debt Off The Books | Occidental Petroleum Corp (NYSE:OXY) has significantly reduced its debt by $5.8 billion after selling its OxyChem divisi | [Link](https://longbridge.com/en/news/276372720.md) |
| IronBridge Private Wealth LLC Has $905,000 Holdings in Apple Inc. $AAPL | IronBridge Private Wealth LLC reduced its stake in Apple Inc. (NASDAQ:AAPL) by 77.3% in Q3, holding 3,555 shares valued  | [Link](https://longbridge.com/en/news/276436345.md) |
| Financial Advocates Investment Management Lowers Stock Position in Meta Platforms, Inc. $META | Financial Advocates Investment Management reduced its stake in Meta Platforms, Inc. by 66.7% in Q3, now holding 2,343 sh | [Link](https://longbridge.com/en/news/276432394.md) |
| Rocket Lab Corporation $RKLB Stock Holdings Increased by Vanguard Group Inc. | Vanguard Group Inc. increased its stake in Rocket Lab Corporation (NASDAQ:RKLB) by 5.4% in Q3, owning 41.8 million share | [Link](https://longbridge.com/en/news/276451972.md) |
| Denali Advisors LLC Lowers Stake in Alphabet Inc. $GOOG | Denali Advisors LLC reduced its stake in Alphabet Inc. (NASDAQ:GOOG) by 27.4% in Q3, now holding 76,983 shares valued at | [Link](https://longbridge.com/en/news/276432387.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
